HIKAL LIMITED (NSE: HIKAL) is a Pharmaceuticals & Biotechnology company listed on NSE and BSE.
It trades at ₹217.39 and carries a market capitalisation of ₹2,685 Cr.
Over the trailing twelve months it reported revenue of ₹1,713 Cr and a net loss of ₹49 Cr.
It shows a five-year median return on equity of 6.9% and a debt-to-equity ratio of 0.57× as of FY26.
This page tracks every NSE and BSE corporate filing for HIKAL LIMITED, each AI-summarised, alongside its financials, shareholding and post-announcement price reactions.
Is this a good business at a fair price?
Auto-derived verdict from fundamentals · as of FY26
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
